<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028673</url>
  </required_header>
  <id_info>
    <org_study_id>19270A</org_study_id>
    <nct_id>NCT05028673</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants</brief_title>
  <official_title>Interventional, Randomized, Open-Label, Crossover, Single-Dose, Relative Bioavailability Study Comparing Two Pharmaceutical Formulations of Lu AG06466 and Investigating the Food Effect on Lu AG06466 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this trial is to learn how a new tablet formulation of Lu AG06466 behaves in&#xD;
      the body. Researchers will compare the new tablet formulation to the capsule formulation that&#xD;
      is currently being tested in other clinical trials. They will measure the levels of the drug&#xD;
      in the bloodstream for up to 3 days after participants take either the tablet or the capsule&#xD;
      formulation. They will also look at whether the tablet formulation behaves differently when&#xD;
      it is taken with and without food.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of 6 sequences with 4 periods (3 days/period) in each sequence. The&#xD;
      first 3 periods will be randomized. Each Lu AG06466 dose administration will be separated by&#xD;
      a washout period of at least 72 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The first 3 periods will be randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity AUC(0-inf) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
    <description>AUC(0-inf) is defined as AUC0-tlast + Clast * t1/2 / ln2 (where Clast is the last quantifiable concentration and t1/2 is the apparent elimination half-life).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of Metabolite Lu AG06988</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
    <description>AUC(0-inf) is defined as AUC0-tlast + Clast * t1/2 / ln2 (where Clast is the last quantifiable concentration and t1/2 is the apparent elimination half-life).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-Time Curve from Zero to Last Quantifiable Concentration (AUC0-tlast) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tlast of Metabolite Lu AG06988</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Metabolite Lu AG06988</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax (Tmax) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Metabolite Lu AG06988</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
    <description>CL/F is defined as dose / AUC0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
    <description>Vz/F is defined as CL/F * t1/2 / ln2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Elimination Half-life (t1/2) of Lu AG06466</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Metabolite Lu AG06988</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Ratio (MR)</measure>
    <time_frame>0 (predose) up to 72 hours postdose on Day 1 to Day 12</time_frame>
    <description>MR is defined as AUC0-inf, Lu AG06988 / AUC0-inf, Lu AG06466.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AG06466 Capsule, Fasted State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 capsule of Lu AG06466 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG06466 Tablet, Fasted State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 tablet of Lu AG06466 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG06466 Tablet, Fed State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG06466 Tablet + Antacid, Fasted State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466 Capsule</intervention_name>
    <description>Hard capsule</description>
    <arm_group_label>Lu AG06466 Capsule, Fasted State</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466 Tablet</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Lu AG06466 Tablet + Antacid, Fasted State</arm_group_label>
    <arm_group_label>Lu AG06466 Tablet, Fasted State</arm_group_label>
    <arm_group_label>Lu AG06466 Tablet, Fed State</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antacid</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>Lu AG06466 Tablet + Antacid, Fasted State</arm_group_label>
    <other_name>Maalox</other_name>
    <other_name>Aluminum hydroxide and magnesium hydroxide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a body mass index (BMI) ≥18.5 and ≤30 kg/m^2 at the Screening&#xD;
             Visit and at the Baseline Visit.&#xD;
&#xD;
          -  The participant is, in the opinion of the investigator, generally healthy based on&#xD;
             medical history; a physical examination; vital signs; an electrocardiogram (ECG); and&#xD;
             the results of the clinical chemistry, hematology, urinalysis, serology, and other&#xD;
             laboratory tests at the Screening Visit and/or the Baseline Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has a personal history of a clinically significant psychiatric&#xD;
             disorder (including severe affective disorder, severe anxiety disorder, psychotic&#xD;
             tendencies, and drug-induced psychoses).&#xD;
&#xD;
          -  The participant has or has had any clinically significant immunological,&#xD;
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,&#xD;
             endocrinological, hematological, dermatological, venereal, neurological, or&#xD;
             psychiatric disease or other major disorder.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

